| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Uremia | D014511 | 33 associated lipids |
| Colitis, Ulcerative | D003093 | 24 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Kidney Failure, Chronic | D007676 | 51 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Graft Occlusion, Vascular | D006083 | 11 associated lipids |
| Hypercalcemia | D006934 | 13 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- J. Pharmacol. Exp. Ther. (1)
- Am. J. Physiol. Renal Physiol. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Shapiro R | Tacrolimus in pediatric renal transplantation: a review. | 1998 | Pediatr Transplant | pmid:10084728 |
| Vieregge B et al. | Synergistic effects of the alkaloid sinomenine in combination with the immunosuppressive drugs tacrolimus and mycophenolic acid. | 1999 | Planta Med. | pmid:10083851 |
| Cirocco RE et al. | Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083604 |
| Fu F et al. | Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083555 |
| Chiba K et al. | FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083549 |
| Hoshino Y et al. | FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083547 |
| Jiang H et al. | Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083538 |
| Schorlemmer HU et al. | Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083529 |
| Wu MS et al. | Cyclosporine, but not FK506 and rapamycin, enhances Na(+)-K(+)-CL- cotransport activity in cultured medullary thick ascending limb cells. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083527 |
| Yamashita K et al. | Effect of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083526 |
| Mohamed MA et al. | The effect of cyclosporin A and tacrolimus on cultured human epithelial cells: the role of TGF-beta. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083523 |
| Zanker B et al. | Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083521 |
| Zuckermann A et al. | Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083518 |
| Kokado Y et al. | Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083515 |
| Opelz G | Immunosuppression with FK 506 does not improve kidney graft survival. Collaborative Transplant Study. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083513 |
| Shapiro R et al. | A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083507 |
| Steinmueller T et al. | The effect of cyclosporine vs FK 506 on glucose metabolism. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083504 |
| Yang HC et al. | Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083501 |
| Klupp J et al. | Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083497 |
| McAlister VC et al. | Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083495 |